Diabetes care in the oncologic population Journal Article
| Authors: | Presswala, L. S.; Farooki, A.; Flory, J. |
| Article Title: | Diabetes care in the oncologic population |
| Abstract: | Diabetes and cancer commonly co-exist, and there are several facets to the management of patients with cancer and diabetes based on their underlying malignancy, tumor burden, choice of cancer treatment, exposure to concomitant medications such as corticosteroids, nutritional state, and goals of care. Glycemic targets for the hospitalized patient aimed for a blood glucose range of 140–180 mg/dL in most critically ill and non-critically ill patients may not be relevant to the oncologic population. In this chapter, we review diabetes care in patients with cancer focusing on the management of glucocorticoid-induced hyperglycemia or glucocorticoid-associated diabetes, chemotherapy-mediated hyperglycemia, immunotherapy-mediated diabetes mellitus, and paraneoplastic hyperglycemia. Many patients with cancer struggle with anorexia at some point or throughout their disease course, and the nutritional status of these patients should also be incorporated in their diabetes management. Finally, diabetes care at the end of life is another focus of this chapter as it pertains to much of the oncologic population. © 2023, The Author(s), under exclusive license to Springer Nature Switzerland AG. |
| Keywords: | overall survival; prednisone; cisplatin; fluorouracil; cancer growth; gemcitabine; paclitaxel; disease free survival; chemotherapy; outcome assessment; endometrium cancer; anorexia; nutritional status; ipilimumab; progression free survival; apoptosis; breast cancer; incidence; palliative therapy; dexamethasone; oncology; cancer therapy; risk factor; cancer mortality; docetaxel; temsirolimus; hyperglycemia; health care; hypokalemia; length of stay; prednisolone; immunotherapy; diabetes mellitus; glucocorticoid; insulin; glucose blood level; hypoglycemia; insulin resistance; metabolic syndrome x; methylprednisolone; terminal care; hazard ratio; hydrocortisone; ketoconazole; mifepristone; drug half life; paraneoplastic syndrome; insulin dependent diabetes mellitus; non insulin dependent diabetes mellitus; life expectancy; everolimus; fulvestrant; glucocorticoids; parenteral nutrition; programmed death 1 ligand 1; nutrition; pharmacokinetic parameters; diabetic ketoacidosis; glycemic control; sulfonylurea; insulin treatment; glycemic index; insulin deficiency; cancer; human; insulin release; pembrolizumab; blood glucose monitoring; durvalumab; elimination half-life; atezolizumab; avelumab; malignant neoplasm; metyrapone; insulin aspart; insulin detemir; insulin glulisine; insulin lispro |
| Journal Title: | Contemporary Endocrinology |
| ISSN: | 2523-3785 |
| Publisher: | Humana Press Inc |
| Date Published: | 2023-01-01 |
| Start Page: | 355 |
| End Page: | 370 |
| Language: | English |
| DOI: | 10.1007/978-3-031-44648-1_24 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book Chapter 24, in "Diabetes management in hospitalized patients: A comprehensive clinical guide" (ISBN: 978-3-031-44647-4) -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work